

### **UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office**

Address: Box ISSUE FEE

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

SCULLY, SCOTT, MURPHY & PRESSER 200 GARDEN CITY PLAZA GARDEN CITY, NY 11530-3391

## NOTICE OF ALLOWANCE AND ISSUE FEE DUE

	Note	attached	communi	cation	from:	the Examir	ier
_ 3							

This notice is issued in view of applicant's communication filed

SERIES CODE/SERIAL NO.		FILING DATE	TOTAL CLAIMS	S EXAMINER AND GROUP ART UNIT		DATE MAILED
	07/042,498	04/24/87	009	HOFFER, F	182	11/20/89
First Named Applicant	O'BRIEN,		M.I. Y	MOTHY J.		

TITLE OF

TUMOR SPECIFIC ASSAY FOR CA125 OVARIAN CANCER ANTIGEN

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN, TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1 6626	435-007.0	00 A82	2 UTILI	TY NO	\$620.0	0 02/20/90

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

#### HOW TO RESPOND TO THIS NOTICE:

I. Review the SMALL ENTITY Status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the Status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
- B. If the Status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by a charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, Part C of this notice should also be completed and returned.
- III. All communications regarding this application must give series code (or filing date), serial number and batch number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees.



# UNITED STATE PARTMENT OF COMMERCE Patent and Trace Park Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
-		٦	EXAMINER
			ART UNIT PAPER NUMBER
			170
			DATE MAILED:
		NOTICE OF ALLOWABILITY	
All the claims herewith (or p course.  The allowed cl.  The drawings of the claims of	aims are	Notice Of Allowance And Issue Fee Due or othe  3-10  are acceptable.  claim for priority under 35 U.S.C. 119. The cerpplication Serial No	r appropriate communication will be sent in due
OM THE "DATE I	MAILED" indicated	OR RESPONSE to comply with the requirements on this form. Failure to timely comply will resorthe provisions of 37 CFR 1.136(a).	
		AMENDMENT or NOTICE OF INFORMAL APPLIC TITUTE OATH OR DECLARATION IS REQUIRED.	ATION, PTO-152, which discloses that the oath
	JST MAKE THE DE	RAWING CHANGES INDICATED BELOW IN THE	MANNER SET FORTH ON THE REVERSE SIDE
-	ormalities are indi . CORRECTION IS F	cated on the NOTICE RE PATENT DRAWINGS REQUIRED.	S, PTO-948, attached hereto or to Paper No.
b.   The propose	ed drawing correcti	on filed on has been	en approved by the examiner. CORRECTION IS
REQUIRED.			
REQUIRED.	rawing corrections	are described by the examiner in the attached	EXAMINER'S AMENDMENT. CORRECTION IS

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

### Attachments:

Examiner's Amendment

Examiner Interview Summary Record, PTOL- 413

- \_ Reasons for Allowance
- Notice of References Cited, PTO-892
- ✓Information Disclosure Citation, PTO-1449

- Notice of Informal Application, PTO-152
- \_ Notice re Patent Drawings, PTO-948
- \_ Listing of Bonded Draftsmen
- \_ Other

SN: 07 642498

DAVID M. NAFF PRIMARY EXAMINER ART UNIT 182 Serial No. 07/042,498 Art Unit 182

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Mr. Frank DiGiglio on November 16, 1989.

The examiner makes the following changes:

- a). in claim 1, line 2, insert --serous cystadinocarcinoma-- after "of"; also on line 2, delete "CA 125" and insert --CA125-- after "antigen";
- b). in claim 3, line 2, insert --molecular weight-- after "dalton", delete "the" and insert --serous cystadinocarcinoma--before the term "ovarian";
- c), in claim 5, delete lines 1-5, and insert \rightarrow A method of detection of ovarian cancer which comprises the steps of contacting the serum of an individual suspected of having the cancer with at least one antibody having specificity for a 40 kilodalton subunit of serous cystadinocarcinoma ovarian tumor associated antigen CA125 and detecting a subunit-antibody reaction.
- d). in claim 6, line 5, insert --molecular weight-- after "kilodalton", delete "ovarian tumor associated", insert --the-- after "of" and insert -- antigen-- after "CA125";
  - e). in claim 6, line 6, insert --the-- after "for";
- f). in claim 6, line 10, delete "ovarian tumor associated" and insert -the-- after the second occurrence of "for";

Serial No. 07/042,498 Art Unit 182

g). in claim 7, line 2 delete "being compartmentalized to receive" and insert --containing--;

h). in claim 7, line 4, insert --molecular weight-- after "kilodalton" and nsert --serous cystadinocarcinoma--before the term "ovarian";

D3

i). in claim 7, line 6, insert --serous cystadinocarcinoma-- before the term "ovarian";

j). in claim 10, line 3, delete the second occurrence of "container".

In the abstract, at page 26, line 3, linsert --serous cystadinocarcinoma ovarian tumor associated antigen-- after "of" and delete "antigen".

An inquiry concerning this communication should be directed to Florina B. Hoffer at telephone number (703) 557-9173.

7134

**FBHOFFER** 

11/16/1989

DAVID M. NAFF
PRIMARY EXAMINER
ART UNIT 182